Clomipramine Hydrochloride Capsules

**Type of Posting**: Revision Bulletin  
**Posting Date**: 07–Jul–2020  
**Official Date**: 08–Jul–2020  
**Expert Committee**: Chemical Medicines Monographs 4  
**Reason for Revision**: Compliance

In accordance with the Rules and Procedures of the 2015–2020 Council of Experts, the Chemical Medicines Monographs 4 Expert Committee has revised the Clomipramine Hydrochloride Capsules monograph. The purpose for the revision is to revise *Dissolution Test 1* to accommodate FDA-approved drug products which use suitable sinkers.

The Clomipramine Hydrochloride Capsules Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Heather Joyce, Senior Scientific Liaison (301-998-6792 or hrj@usp.org).
Clomipramine Hydrochloride Capsules

DEFINITION
Clomipramine Hydrochloride Capsules contain NLT 90.0% and NMT 110.0% of the labeled amount of clomipramine hydrochloride (C19H23ClN2·HCl).

IDENTIFICATION
• A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
• B. The UV spectrum of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY
• PROCEDURE
  Solution A: Add 2.5 mL of acetic acid to 1 L of water. Adjust with stronger ammonia water to a pH of 7.5.
  Solution B: Acetonitrile, methanol, and stabilizer-free tetrahydrofuran (80:15:5)
  Mobile phase: See Table 1.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solution A (%)</th>
<th>Solution B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>2.0</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>5.0</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>11.0</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>14.0</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>14.1</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>18.0</td>
<td>65</td>
<td>35</td>
</tr>
</tbody>
</table>

Diluent: Solution A and acetonitrile (50:50)
System suitability solution: 0.2 mg/mL of USP Clomipramine Hydrochloride RS and 0.005 mg/mL of USP Clomipramine Related Compound A RS in Diluent
Standard solution: 0.2 mg/mL of USP Clomipramine Hydrochloride RS in Diluent
Sample solution: Nominally 0.2 mg/mL of clomipramine hydrochloride from Capsules in Diluent prepared as follows. Transfer a sufficient portion of the contents of Capsules (NLT 20) to a suitable volumetric flask. Add 60% of the final flask volume of Diluent. Shake by mechanical means for about 30 min. Dilute with Diluent to volume. Centrifuge to obtain a clear supernatant and use the clear supernatant. [Note—The use of a centrifuge speed of 3000 rpm for 10 min may be suitable.]

Chromatographic system
(See Chromatography (621), System Suitability.)
  Mode: LC
  Detector: UV 254 nm. For Identification B, use a diode array detector in the range of 200–400 nm.
**Column:** 2.1-mm × 10-cm; 1.7-µm packing

**Column temperature:** 30°

**Flow rate:** 0.3 mL/min

**Injection volume:** 2 µL

**System suitability**

**Samples:** System suitability solution and Standard solution

[NOTE—See Table 2 for relative retention times.]

**Suitability requirements**

**Resolution:** NLT 2.0 between clomipramine and clomipramine related compound A, System suitability solution

**Relative standard deviation:** NMT 1.0%, Standard solution

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of clomipramine hydrochloride \( \left( \text{C}_{19}\text{H}_{23}\text{ClN}_2 \cdot \text{HCl} \right) \) in the portion of Capsules taken:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

- \( r_U \) = peak response from the Sample solution
- \( r_S \) = peak response from the Standard solution
- \( C_S \) = concentration of USP Clomipramine Hydrochloride RS in the Standard solution (mg/mL)
- \( C_U \) = nominal concentration of clomipramine hydrochloride in the Sample solution (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

**PERFORMANCE TESTS**

**Change to read:**

- **Dissolution (711)**

**Test 1**

**Medium:** 0.1 N hydrochloric acid VS; 500 mL

**Apparatus 2:** 50 rpm. ▲With suitable sinkers, if needed. ▲(RB 8-Jul-2020)

**Time:** 30 min

**Standard solution:** USP Clomipramine Hydrochloride RS in Medium

**Sample solution:** Pass the solution under test through a suitable filter and use the filtrate. Dilute with Medium, if necessary, to a concentration that is similar to the Standard solution.

**Instrumental conditions**

(See Ultraviolet-Visible Spectroscopy (857).)

**Mode:** UV

**Analytical wavelength:** 252 nm

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of clomipramine hydrochloride \( \left( \text{C}_{19}\text{H}_{23}\text{ClN}_2 \cdot \text{HCl} \right) \) dissolved:

\[
\text{Result} = \left( \frac{A_U}{A_S} \right) \times C_S \times D \times V \times \left( \frac{1}{L} \right) \times 100
\]

- \( A_U \) = absorbance of the Sample solution
- \( A_S \) = absorbance of the Standard solution
\( C_S \) = concentration of USP Clomipramine Hydrochloride RS in the Standard solution (mg/mL)

\( D \) = dilution factor for the Sample solution

\( V \) = volume of Medium, 500 mL

\( L \) = label claim (mg/Capsule)

**Tolerances:** NLT 80% (Q) of the labeled amount of clomipramine hydrochloride \((C_{19}H_{23}ClN_2 \cdot HCl)\) is dissolved.

**Test 2:** If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2.

**Medium:** 0.01 N hydrochloric acid TS; 500 mL

**Apparatus 2:** 75 rpm with sinkers

**Time:** 15 min

**Solution A:** 55 g/L of sodium 1-heptanesulfonate in solution prepared as follows. Transfer a suitable amount of sodium 1-heptanesulfonate to an appropriate volumetric flask. Add 50% of the flask volume of water and dilute with glacial acetic acid to volume.

**Solution B:** To an appropriate volumetric flask, add 4% of the flask volume of Solution A and 0.4% of the flask volume of triethylamine. Dilute with water to volume.

**Mobile phase:** To an appropriate volumetric flask, add 50% of the flask volume of Solution B. Adjust the resulting solution with phosphoric acid to a pH of 3.2. Dilute with acetonitrile to volume.

**Standard stock solution:** 0.5 mg/mL of USP Clomipramine Hydrochloride RS in Medium. Sonication may be used to promote dissolution.

**Standard solution:** \((L/500)\) mg/mL of USP Clomipramine Hydrochloride RS from the Standard stock solution in Medium, where \( L \) is the label claim in mg/Capsule

**Sample solution:** Pass a portion of the solution under test through a suitable filter and discard NLT the first 5 mL of filtrate.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing \( L_1 \)

**Column temperature:** 35°

**Flow rate:** 1.5 mL/min

**Injection volume:** 10 μL

**Run time:** NLT 1.4 times the retention time of clomipramine

**System suitability**

**Sample:** Standard solution

**Suitability requirements**

- **Tailing factor:** 0.8–2.0
- **Relative standard deviation:** NMT 1.0%

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of clomipramine hydrochloride \((C_{19}H_{23}ClN_2 \cdot HCl)\) dissolved:

\[
\text{Result} = \left(\frac{r_U}{r_S}\right) \times C_S \times V \times \left(\frac{1}{L}\right) \times 100
\]

\( r_U \) = peak response from the Sample solution

\( r_S \) = peak response from the Standard solution
\[ C_S = \text{concentration of USP Clomipramine Hydrochloride RS in the Standard solution (mg/mL)} \]

\[ V = \text{volume of the Medium, 500 mL} \]

\[ L = \text{label claim of clomipramine hydrochloride (mg/Capsule)} \]

**Tolerances:** NLT 80% \((Q)\) of the labeled amount of clomipramine hydrochloride \((C_{19}H_{23}ClN_2 \cdot HCl)\) is dissolved.

- **Uniformity of Dosage Units (905).**

**Procedure for content uniformity**

**Standard solution:** 30 \(\mu\text{g/mL}\) of USP Clomipramine Hydrochloride RS in methanol

**Sample stock solution:** Transfer the contents of 1 Capsule to a 100-mL volumetric flask with the aid of methanol. Add about 75 mL of methanol, shake by mechanical means for 1 h, and dilute with methanol to volume.

**Sample solution:** Nominally 30 \(\mu\text{g/mL}\) of clomipramine hydrochloride from the Sample stock solution in methanol

**Instrumental conditions**

(See Ultraviolet-Visible Spectroscopy (857).)

- **Mode:** UV
- **Analytical wavelength:** 252 nm
- **Cell:** 1 cm
- **Blank:** Methanol

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of clomipramine hydrochloride \((C_{19}H_{23}ClN_2 \cdot HCl)\) in the Capsule taken:

\[
\text{Result} = \left( \frac{A_U}{A_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

\[ A_U = \text{absorbance of the Sample solution} \]

\[ A_S = \text{absorbance of the Standard solution} \]

\[ C_S = \text{concentration of USP Clomipramine Hydrochloride RS in the Standard solution (\(\mu\text{g/mL}\))} \]

\[ C_U = \text{nominal concentration of clomipramine hydrochloride in the Sample solution (\(\mu\text{g/mL}\))} \]

**Acceptance criteria:** Meet the requirements

**IMPURITIES**

- **Organic Impurities**

**Solution A, Solution B, Mobile phase, Diluent, and Chromatographic system:** Proceed as directed in the Assay.

**System suitability solution:** 0.5 mg/mL of USP Clomipramine Hydrochloride RS and 0.0025 mg/mL of USP Clomipramine Related Compound A RS in Diluent

**Standard solution:** 0.0025 mg/mL each of USP Clomipramine Hydrochloride RS, USP Clomipramine Related Compound C RS, and USP Imipramine Hydrochloride RS in Diluent

**Sample solution:** Nominally 0.5 mg/mL of clomipramine hydrochloride from Capsules in Diluent prepared as follows. Transfer a sufficient portion of the contents of Capsules (NLT 20) to a suitable volumetric flask. Add 60% of the final flask volume of Diluent. Shake by mechanical means for about 30 min. Dilute with Diluent to volume. Centrifuge to obtain a clear supernatant and use the clear supernatant. [Note—The use of a centrifuge speed of 3000 rpm for 10 min may be suitable.]

**System suitability**
**Samples:** System suitability solution and Standard solution

[Note—See Table 2 for relative retention times.]

**Suitability requirements**

- **Resolution:** NLT 2.0 between clomipramine and clomipramine related compound A, System suitability solution
- **Relative standard deviation:** NMT 5.0% for all standard peaks, Standard solution

**Analysis**

**Samples:** Standard solution and Sample solution

Calculate the percentage of each specified impurity in the portion of Capsules taken:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

\( r_U \) = peak response of each specified impurity from the *Sample solution*

\( r_S \) = peak response of the corresponding USP Reference Standard from the *Standard solution*

\( C_S \) = concentration of the corresponding USP Reference Standard in the *Standard solution* (mg/mL)

\( C_U \) = nominal concentration of clomipramine hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of each unspecified impurity in the portion of Capsules taken:

\[
\text{Result} = \left( \frac{r_U}{r_S} \right) \times \left( \frac{C_S}{C_U} \right) \times 100
\]

\( r_U \) = peak response of each unspecified impurity from the *Sample solution*

\( r_S \) = peak response of clomipramine from the *Standard solution*

\( C_S \) = concentration of USP Clomipramine Hydrochloride RS in the *Standard solution* (mg/mL)

\( C_U \) = nominal concentration of clomipramine hydrochloride in the *Sample solution* (mg/mL)

**Acceptance criteria:** See Table 2. The reporting threshold is 0.03%.

**Table 2**

<table>
<thead>
<tr>
<th>Name</th>
<th>Relative Retention Time</th>
<th>Acceptance Criteria, NMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipramine</td>
<td>0.77</td>
<td>1.0</td>
</tr>
<tr>
<td>Clomipramine related compound C</td>
<td>0.87</td>
<td>0.5</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Clomipramine related compound A&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Clomipramine related compound D&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Clomipramine related compound F&lt;sup&gt;a,c&lt;/sup&gt;</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Any individual unspecified impurity</td>
<td>—</td>
<td>0.5</td>
</tr>
<tr>
<td>Total impurities</td>
<td>—</td>
<td>2.0</td>
</tr>
</tbody>
</table>

<sup>a</sup> Process impurity included in the table for identification only. Process impurities are controlled in the drug substance, and are not to be reported or included in the total impurities for the drug product.
b 3-(3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride.

c 3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepine.

ADDITIONAL REQUIREMENTS

• **Packaging and Storage:** Preserve in tight, light-resistant containers. Protect from moisture. Store at controlled room temperature.

• **Labeling:** The labeling states the *Dissolution* test used only if *Test 1* is not used.

• **USP Reference Standards.**
  - USP Clomipramine Hydrochloride RS
  - USP Clomipramine Related Compound A RS
  - USP Clomipramine Related Compound C RS
  - USP Imipramine Hydrochloride RS

  \[-\begin{align*}
  N^1\text{-}[3\text{-}(3\text{-Chloro-10,11\text{-dihydro-5H\text{-dibenzo}}[b,f]\text{azepin-5-yl})\text{propyl}]\text{-}N^1,N^3,N^3\text{-trimethylpropane-1,3-diamine dihydrochloride.} \\
  \text{C}_{23}\text{H}_{32}\text{ClN}_3 \cdot 2\text{HCl} & 458.89 \\
  \text{USP Clomipramine Related Compound C RS} \\
  3\text{-}(3\text{-Chloro-5H\text{-dibenzo}}[b,f]\text{azepin-5-yl})\text{-}N,N\text{-dimethylpropan-1-amine hydrochloride, monohydrate.} \\
  \text{C}_{19}\text{H}_{21}\text{ClN}_2 \cdot \text{HCl} \cdot \text{H}_2\text{O} & 367.31 \\
  \text{USP Imipramine Hydrochloride RS}
\end{align*}\]

Page Information:
Not Applicable

DocID: © 2020 The United States Pharmacopeial Convention All Rights Reserved.